Ureteral carcinoma in situ after successful intravesical therapy for superficial bladder tumors: incidence, possible pathogenesis and management. Academic Article uri icon

Overview

abstract

  • A total of 66 patients with multifocal, progressive, flat carcinoma in situ of the bladder responded completely to intravesical bacillus Calmette-Guerin therapy for more than 1 year. Of the patients 19 (29 per cent) had clinical evidence of distal ureteral carcinoma in situ between 13 and 30 months (median 15 months) after bacillus Calmette-Guerin treatment. After evaluation of a positive urinary cytology study failed to reveal recurrent urothelial tumor of the bladder or prostatic urethral mucosa 6 patients underwent distal ureterectomy, 2 underwent nephroureterectomy, and 11 were managed by ureteroscopic resection and fulguration. In patients with carcinoma in situ of the bladder treated successfully with topical therapy the ureters represent a potential site of in situ carcinoma.

publication date

  • August 1, 1987

Research

keywords

  • BCG Vaccine
  • Carcinoma in Situ
  • Ureteral Neoplasms
  • Urinary Bladder Neoplasms

Identity

Scopus Document Identifier

  • 0023234578

Digital Object Identifier (DOI)

  • 10.1016/s0022-5347(17)43123-5

PubMed ID

  • 3599241

Additional Document Info

volume

  • 138

issue

  • 2